Overview
Dentsply Sirona appoints Daniel Scavilla as CEO, effective August 1, 2025
Company reports preliminary Q2 2025 revenue of $935 mln, beating expectations
Adjusted EPS for Q2 2025 expected between $0.50 and $0.52
Outlook
Company reaffirms 2025 outlook from May 8 earnings release
Dentsply Sirona expects Q2 2025 net sales of $935 mln
Company anticipates Q2 2025 adjusted EPS between $0.50 and $0.52
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Preliminary revenue | Beat | $935 mln | $933.10 mln (13 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 14 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for DENTSPLY SIRONA Inc is $17.00, about 7.8% above its July 18 closing price of $15.68
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 8 three months ago
Press Release: ID:nGNX8BX9zy
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.